The identification of lectins that bind predominantly to KRAS mutant organoids compared to KRAS wild-type organoids may contribute to the development of markers that recognize KRAS mutant pancreatic cancer cells and cancer proteins for CTC and hematological diagnosis. This evidence concerns the gene KRAS and familial pancreatic carcinoma.